Psyence Biomedical Ltd. Common Shares (PBM)
PBM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PBM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001985062 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | ON |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-06-22 |
| Cash and burn | $7.4M cash; operating cash flow -$2.0M a quarter. | Report 2026-03-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-03-31 |
| Reverse splits, 3 years | 4; latest 1-for-6.25 on 2026-02-02 | Source 2026-02-02 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-08-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MNP LLP, Toronto, Canada | PCAOB Form AP 2026-06-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | Not filed | -$6.9M | -$8.1M | $7.4M | $251K | Needs four quarters | 20-F 2026-06-22 |
| FY 2025 2025-03-31 | Not filed | $1.0M | -$3.7M | $6.1M | No debt tags | Needs four quarters | 20-F 2025-06-25 |
| FY 2024 2024-03-31 | Not filed | -$51.2M | -$2.9M | $733K | $10.4M | Needs four quarters | 20-F 2025-06-25 |
| FY 2023 2023-03-31 | Not filed | -$3.2M | -$1.6M | $1.3M | No debt tags | Needs four quarters | 20-F 2025-06-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-08-26 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-06-22 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-21 |
Source: SEC EDGAR submissions feed, 170 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.3% |
| 1 month | -30.9% |
| 3 months | -11.7% |
| Year to date | -89.3% |
| 1 year | -97.1% |
| From 52-week high | -97.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| PBMWW | Psyence Biomedical Ltd. Warrant | $0.0121 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| NCEL | NewcelX Ltd. | $2.75 | +5.36% | $15.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier